Companies › Cellectis
3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| UCART20x22 Allogeneic engineered T-cells expressing anti-CD20 and anti-CD22 Chimeric Antigen Receptor | CD20, CD22 | Phase 1 | B-cell Non-Hodgkin Lymphoma (B-NHL) | Aug 2027 |
| UCART123v1.2 Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor | CD123 | Phase 1 | Relapsed/Refractory Acute Myeloid Leukemia | – |
| UCART22 Allogeneic engineered T-cells expressing anti-CD22 chimeric antigen receptor (CAR-T) | CD22 | Phase 1 | B-cell Acute Lymphoblastic Leukemia | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03190278 | UCART123v1.2 | Phase 1 | Relapsed/Refractory Acute Myeloid Leukemia | Oncology | Dec 2024 |
| NCT04150497 | UCART22 | Phase 1 | B-cell Acute Lymphoblastic Leukemia | Oncology | Jun 2026 |
| NCT05607420 | UCART20x22 | Phase 1 | B-cell Non-Hodgkin Lymphoma (B-NHL) | Oncology | Aug 2027 |
Cash of $62m on 2025-12-31; operating cash outflow about $40m a year; runway about 19 months at that burn, to Jul 2027
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.